Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Free Cash Flow (2018 - 2025)

10x Genomics (TXG) has disclosed Free Cash Flow for 8 consecutive years, with $40.7 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 2479.02% to $40.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $135.8 million through Dec 2025, up 2456.65% year-over-year, with the annual reading at $135.8 million for FY2025, 2456.65% up from the prior year.
  • Free Cash Flow hit $40.7 million in Q4 2025 for 10x Genomics, down from $43.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $62.5 million in Q4 2021 to a low of -$92.4 million in Q3 2021.
  • Historically, Free Cash Flow has averaged -$6.3 million across 5 years, with a median of -$4.2 million in 2021.
  • Biggest five-year swings in Free Cash Flow: plummeted 881.39% in 2022 and later surged 2479.02% in 2025.
  • Year by year, Free Cash Flow stood at $62.5 million in 2021, then crashed by 241.85% to -$88.6 million in 2022, then skyrocketed by 125.16% to $22.3 million in 2023, then tumbled by 92.93% to $1.6 million in 2024, then soared by 2479.02% to $40.7 million in 2025.
  • Business Quant data shows Free Cash Flow for TXG at $40.7 million in Q4 2025, $43.4 million in Q3 2025, and $19.3 million in Q2 2025.